Skip to content
RGNX·Nasdaq·US

REGENXBIO

REGENXBIO is a clinical-stage biotechnology company developing investigational gene therapies using adeno-associated virus (AAV) vectors from its proprietary NAV Technology Platform to treat genetic diseases, focusing internally on retinal, neuromuscular and neurodegenerative diseases. It sells/licenses its technology to biopharmaceutical partners such as AbbVie and Nippon Shinyaku and to NAV Technology Licensees such as Novartis, positioning itself as a leading platform company within the gene therapy industry.

Source: SEC 10-K Mar 5, 2026

Thematic Position

RGNX

Relationship Groups

Customers1
Partners1
Licensing6
Competitors15

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government funding rightsmarch-in rights
U.S. government march-in rights over federally funded patent technology
SEC 10-KMar 5, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

2 customers · Named major customers are part of the Pro plan.